HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec OTC Patent Extension Submission Pending At PTO

This article was originally published in The Tan Sheet

Executive Summary

AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity

You may also be interested in...



Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues

Perrigo has acquired marketing rights for a potential generic version of Prilosec OTC, but litigation against the firm's partner Dexcel Pharma by AstraZeneca could block generic OTC omeprazole through 2019

Generic Prilosec OTC Capsules Suitable For ANDA Submission – FDA

FDA clears the way for an ANDA filing for capsules equivalent to Prilosec OTC tablets (omeprazole magnesium 20mg) in a July 6 response to a suitability petition

Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions

A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS128172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel